In mouse models, MEK inhibitors were found to inhibit tumour growth via increasing the number of intertumoral effector-phenotype CD8+ T cells, and combination therapy with both MEK inhibitors and anti-PD-L1 agents exhibited a synergistic effect on antitumor growth (21). Here, MAP2K7 is linked to neoplasm.